

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Please cancel claims 1-68 and add new claims 69-78.

69. (New) A chimeric peptide comprising:

a peptide having a first portion and a second portion, wherein the carboxyl terminus of the first portion is linked to the amino terminus of the second portion; and,

wherein the first portion is from the free N-terminus of a naturally-occurring internal peptide cleavage product which, when naturally-occurring in a mammal, is derived from a precursor protein or a mature protein and the second portion comprises a T helper cell epitope; or,

wherein the first portion comprises a T helper cell epitope and the second portion is from the free C-terminus of said naturally-occurring internal peptide cleavage product.

70. (New) The chimeric peptide according to claim 69, wherein said internal cleavage product is an amyloid β peptide, which when naturally-occurring, is derived from cleavage of β amyloid precursor protein (β APP).

71. (New) The chimeric peptide according to claim 70, wherein said internal peptide cleavage product has an amino acid sequence selected from the group consisting of A β 1-39, A β 1-40, A β 1-41, A β 1-42, and A β 1-43.

72. (New) The chimeric peptide according to claim 69, wherein the first portion is A β 1-3, A β 1-4, or A β 1-5 from the free N-terminus of said internal peptide cleavage product.

73. (New) The chimeric peptide according to claim 69, wherein the first portion is A β 35-40 or A β 35-42 from the free C-terminus of said internal peptide cleavage product.

74. (New) The chimeric peptide according to claim 69, wherein said T helper cell epitope binds to multiple MHC molecules.

75. (New) The chimeric peptide according to claim 69, wherein said T helper cell epitope is derived from tetanus toxoid, diphtheria toxoid, hepatitis B surface antigen, Malaria CS, *E. coli* toxoid, or a toxoid from other pathogenic bacteria.

76. (New) The chimeric peptide according to claim 75, wherein said T helper cell epitope has an amino acid sequence selected from the group consisting of SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 49, and SEQ ID NO: 50.

77. (New) An immunogenic composition, comprising an immunogenically effective amount of the chimeric peptide according to claim 69 and a pharmaceutically acceptable carrier, excipient, diluent, or adjuvant.

78. (New) The immunogenic composition according to claim 77, wherein said adjuvant is alum.